VKTX - Viking Therapeutics Announces Positive Topline Results from Maintenance Study of GLP-1/GIP Agonist VK2735 Demonstrating the Promise of Multiple Maintenance Dosing Regimens

Viking Therapeutics reported positive topline results from its VK2735 maintenance study, showing 22% placebo-adjusted weight loss at Week 33 and successful maintenance with less-frequent dosing.Key Highlights:Original SEC Filing: Viking Therapeutics, Inc. [ VKTX ] - 8-K - Sep. 22, 2026This is an AI…